Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 347

1.

Incidence of and risk factors for medical care interruption in people living with HIV in recent years.

Fournier AL, Yazdanpanah Y, Verdon R, Lariven S, Mackoumbou-Nkouka C, Phung BC, Papot E, Parienti JJ, Landman R, Champenois K.

PLoS One. 2019 Mar 13;14(3):e0213526. doi: 10.1371/journal.pone.0213526. eCollection 2019.

2.

Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.

Lê MP, Valantin MA, Assoumou L, Soulie C, Le Mestre S, Weiss L, Yazdanpanah Y, Molina JM, Bouchaud O, Raffi F, Reynes J, Calvez V, Marcelin AG, Costagliola D, Katlama C, Peytavin G; ANRS-163 ETRAL study group.

Pharmacotherapy. 2019 Feb 27. doi: 10.1002/phar.2242. [Epub ahead of print]

PMID:
30815916
3.

HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.

Perrier M, Castain L, Regad L, Todesco E, Landman R, Visseaux B, Yazdanpanah Y, Rodriguez C, Joly V, Calvez V, Marcelin AG, Descamps D, Charpentier C.

J Antimicrob Chemother. 2019 Feb 14. pii: dkz043. doi: 10.1093/jac/dkz043. [Epub ahead of print]

PMID:
30768160
4.

Illicit massive silicone injections always induce chronic and definitive silicone blood diffusion with dermatologic complications.

Bertin C, Abbas R, Andrieu V, Michard F, Rioux C, Descamps V, Yazdanpanah Y, Bouscarat F.

Medicine (Baltimore). 2019 Jan;98(4):e14143. doi: 10.1097/MD.0000000000014143.

5.

Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.

Perrineau S, Lachâtre M, Lê MP, Rioux C, Loubet P, Fréchet-Jachym M, Gonzales MC, Grall N, Bouvet E, Veziris N, Yazdanpanah Y, Peytavin G.

Int J Tuberc Lung Dis. 2019 Jan 1;23(1):99-104. doi: 10.5588/ijtld.18.0042.

PMID:
30674381
6.

Metabolic syndrome and endocrine status in HIV-infected transwomen.

Pommier JD, Laouénan C, Michard F, Papot E, Urios P, Boutten A, Peytavin G, Ghander C, Lariven S, Castanedo G, Moho D, Landman R, Phung B, Perez E, Julia Z, Descamps D, Roland-Nicaise P, Le Gac S, Yazdanpanah Y, Guibourdenche J, Yeni P.

AIDS. 2019 Apr 1;33(5):855-865. doi: 10.1097/QAD.0000000000002152.

PMID:
30664006
7.

Orogenital Transmission of Neisseria meningitidis Causing Acute Urethritis in Men Who Have Sex with Men.

Jannic A, Mammeri H, Larcher L, Descamps V, Tosini W, Phung B, Yazdanpanah Y, Bouscarat F.

Emerg Infect Dis. 2019 Jan;25(1):175-176. doi: 10.3201/eid2501.171102.

8.

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y; LAMIDOL Study Group .

J Antimicrob Chemother. 2019 Mar 1;74(3):739-745. doi: 10.1093/jac/dky467.

PMID:
30476165
9.

Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study.

Lê MP, Chaix ML, Raffi F, Chevret S, Gallien S, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS-165 DARULIGHT study group.

Br J Clin Pharmacol. 2019 Jan;85(1):277-280. doi: 10.1111/bcp.13796. Epub 2018 Nov 12. No abstract available.

PMID:
30421447
10.

A case of thoracic actinomycosis presenting as sudden paraplegia.

Peiffer-Smadja N, Harent S, Messeca C, Lechapt-Zalcman E, Yazdanpanah Y, Joly V.

Rev Neurol (Paris). 2019 Jan - Feb;175(1-2):89-92. doi: 10.1016/j.neurol.2018.01.380. Epub 2018 Oct 8. No abstract available.

PMID:
30309660
11.

Assessing the cost-effectiveness of hepatitis C screening strategies in France.

Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y.

J Hepatol. 2018 Oct;69(4):785-792. doi: 10.1016/j.jhep.2018.05.027. Epub 2018 Jul 1.

PMID:
30227916
12.

Prevention of Ebola virus disease through vaccination: where we are in 2018.

Lévy Y, Lane C, Piot P, Beavogui AH, Kieh M, Leigh B, Doumbia S, D'Ortenzio E, Lévy-Marchal C, Pierson J, Watson-Jones D, Nguyen VK, Larson H, Lysander J, Lacabaratz C, Thiebaut R, Augier A, Ishola D, Kennedy S, Chêne G, Greenwood B, Neaton J, Yazdanpanah Y.

Lancet. 2018 Sep 1;392(10149):787-790. doi: 10.1016/S0140-6736(18)31710-0. Epub 2018 Aug 10. No abstract available.

13.

Contribution of brain imaging to the diagnosis of intracranial tuberculoma and other brain lesions in patients presenting with miliary tuberculosis.

Bleibtreu A, Grall N, Laissy JP, Rioux C, Strukov A, Lariven S, Yeni P, Yazdanpanah Y, Joly V.

Med Mal Infect. 2018 Dec;48(8):533-539. doi: 10.1016/j.medmal.2018.06.006. Epub 2018 Jul 13.

PMID:
30017477
14.

Calendar trends in sexual behaviours in a cohort of HIV-infected MSM at the era of treatment as prevention of HIV infection.

Champenois K, Seng R, Persoz A, Essat A, Gaud C, Laureillard D, Robineau O, Duvivier C, Yazdanpanah Y, Goujard C, Meyer L; ANRS PRIMO cohort study group.

AIDS. 2018 Aug 24;32(13):1871-1879. doi: 10.1097/QAD.0000000000001916.

PMID:
29927787
15.

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.

Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS 165 DARULIGHT Study Group .

J Antimicrob Chemother. 2018 Aug 1;73(8):2120-2128. doi: 10.1093/jac/dky193.

PMID:
29905808
16.

Costs associated with hospitalization in HIV-positive patients in France.

de Léotoing L, Yazdanpanah Y, Finkielsztejn L, Chaize G, Vainchtock A, Nachbaur G, Aubin C, Bonnet F.

AIDS. 2018 Sep 10;32(14):2059-2066. doi: 10.1097/QAD.0000000000001907.

PMID:
29894390
17.

Plague: Bridging gaps towards better disease control.

D'Ortenzio E, Lemaître N, Brouat C, Loubet P, Sebbane F, Rajerison M, Baril L, Yazdanpanah Y.

Med Mal Infect. 2018 Aug;48(5):307-317. doi: 10.1016/j.medmal.2018.04.393. Epub 2018 Jun 1. Review.

PMID:
29773334
18.

Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness.

Luong Nguyen LB, Yazdanpanah Y, Maman D, Wanjala S, Vandenbulcke A, Price J, Parker RA, Hennequin W, Mendiharat P, Freedberg KA.

Clin Infect Dis. 2018 Aug 16;67(5):719-726. doi: 10.1093/cid/ciy173.

19.

Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.

Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Mabileau G, Dhersin JS, Yazdanpanah Y.

J Viral Hepat. 2018 Oct;25(10):1197-1207. doi: 10.1111/jvh.12919. Epub 2018 May 9.

PMID:
29660211
20.

[The plague: An overview and hot topics].

Galy A, Loubet P, Peiffer-Smadja N, Yazdanpanah Y.

Rev Med Interne. 2018 Nov;39(11):863-868. doi: 10.1016/j.revmed.2018.03.019. Epub 2018 Apr 5. Review. French.

PMID:
29628173

Supplemental Content

Loading ...
Support Center